TFE3 and alveolar soft part sarcoma: In addition to ALK-positive IMT as discussed above, given that ASPS is characterized by translocation between chromosomes 17 and X resulting in ASPSCR1-TFE3 fusion gene and MET overexpression, crizotinib has been studied in the treatment of advanced or metastatic ASPS (76).